GLP-1 Market to Double by 2030 as Obesity and Cardiometabolic Care Drive Expansion — STRATEGIC MARKET RESEARCH LLP

Event summary

Global GLP-1 receptor agonists market projected to grow from $18.4B in 2024 to $41.5B by 2030, a 12.3% CAGR.
Injectables dominate with 82% market share in 2024, but oral formulations are the fastest-growing segment.
Type 2 diabetes accounts for 68% of revenue, while obesity treatment is the fastest-expanding demand pool.
North America leads with 70% market share, with the U.S. market expected to reach $24.4B by 2030.
Asia Pacific is the fastest-growing region, expanding at a 15.3% CAGR through 2030.

The big picture

The GLP-1 receptor agonists market is evolving beyond diabetes treatment into a central platform for obesity and cardiometabolic care. This shift is driven by the growing prevalence of metabolic diseases and the need for therapies that address multiple risk factors simultaneously. The market's expansion will depend on manufacturers' ability to deliver differentiated clinical profiles, scalable supply, and payer-aligned access models.

What we're watching

Regulatory Dynamics: Whether payer policies and reimbursement rules will keep pace with the expanding use of GLP-1 therapies in obesity and cardiometabolic care.
Competitive Positioning: How manufacturers will differentiate through clinical outcomes, manufacturing scale, and affordability strategies.
Market Access: The pace at which emerging markets like India and Asia Pacific will adopt GLP-1 therapies, given affordability and infrastructure challenges.